Valence ロゴ
人気
ログイン
Loading data for ADPT — first visit, this takes a few seconds.

ウォッチリストに追加

Adaptive Biotechnologies ...

NasdaqGS: ADPT · リアルタイム株価 · USD
26.16
-0.09 (-0.34%)
終値時点： Aug 26, 2026, 8:00 PM
26.46
+1.15%
寄り付き前: 8:21 AM

株価、主要な数字、最新ニュースをひとまとめにしたページです。

Adaptive Biotechnologies Corporation（ADPT）の株価・分析・データ

-0.34%

データがありません

買気配18.7
時価総額4.18B
売上高（TTM）308.08M
純利益（TTM）-63.85M
2.09
-0.4
n/a
-141.61
PBR（TTM）29.13
PSR（TTM）13.55
決算発表日Nov 4, 2026
売気配33.28
出来高1,387,087
平均出来高（20日）2,946,103
始値26.00
前日終値26.25
当日レンジ25.82 - 26.51
52週レンジ12.00 - 26.51
アナリストn/a
目標株価n/a
配当n/a
権利落ち日n/a

ADPTについて

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining num...

[続きを読む]
業種 Diagnostics & Research
セクター Healthcare
IPO日 Jun 27, 2019
従業員数 624
上場取引所 NasdaqGS
ティッカー ADPT
ウェブサイト https://www.adaptivebiotech.com
企業情報の全文

業績

2025年のAdaptive Biotechnologiesの売上高は276.98Mで、前年の178.96Mから54.77%の増加でした。 利益は-59.5Mで、-62.69%の減少でした。

財務諸表

決算サプライズ

Adaptive BiotechnologiesはJul 29, 2026に四半期決算を発表しました：
  • 売上高は n/a で、予想を下回りました $0, うち -100.00% の前年比減少.
  • EPSは -0.25 で、予想を下回りました -0.12, うち -47.06% の前年比減少.

次回決算発表

Adaptive Biotechnologies Corporationの決算発表予定日は Nov 4, 2026, 取引時間中の予定です。
アナリストの売上高予想は ... アップグレード
news image

3日前 · Trefis

What Is Really Moving Tempus AI Stock Right Now?

While traders pointed to external clinical-trial momentum as a major catalyst, Tempus's own recent guidance raise and narrowing losses provided the underlying backdrop.

news image

6日前 · Barchart

Adaptive Biotechnologies Stock Has Doubled in the Past Year. Here’s What Could Come Next.

Adaptive Biotechnologies (ADPT) has surged 100% over the past year, driven by strong technical momentum. Shares recently hit a new 3-year high. Analyst sentiment is mixed with price targets ranging fr...

news image

4週間前 · GuruFocus.com

Adaptive Biotechnologies Corp (ADPT) (Q2 2026) Earnings Call Highlights: MRD Revenue Surges ...

Adaptive Biotechnologies Corp (ADPT) reports a strong Q2 with MRD revenue up 49% (ex-milestones) and raises full-year guidance, while progressing the separation of its Immune Medicine business.

news image

4週間前 · Zacks

Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key m...

news image

4週間前 · Zacks

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stoc...

2ページ中1ページ